German Bundesrat insists on 'real price' disclosure
This article was originally published in Scrip
Executive Summary
With the pharmaceutical industry increasingly seeking reimbursement on the basis of 'real-world data' on effectiveness, German politicians are now insisting on transparency on 'real prices' for drugs. On 21 September, the Bundesrat, German's Federal Council which has to endorse legislation administered by the country's regional governments, formally approved amendments to the AMNOG healthcare reform law that mean that any price discounts negotiated between pharmaceutical companies and health insurers in Germany will be publically available.